Arginase inhibition alleviates hypertension in the metabolic syndrome

British Journal of Pharmacology

Volumn 169, Issue 3, 2013, Pages 693-703

  El Bassossy, Hany M ^a,b   El Fawal, Rania ^a   Fahmy, Ahmed ^a   Watson, Malcolm L ^c  

^a Zagazig University   (Egypt)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^c University of Bath   (United Kingdom)

Author keywords

aorta; arginase; citrulline; hypertension; metabolic syndrome; norvaline

Indexed keywords

ACETYLCHOLINE; ARGINASE; CHOLESTEROL; CITRULLINE; GLUCOSE; INSULIN; NORVALINE; ORNITHINE; REACTIVE OXYGEN METABOLITE; TRIACYLGLYCEROL; URIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ENZYME ACTIVITY; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPID COMPOSITION; MALE; METABOLIC SYNDROME X; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL; VASOCONSTRICTION; VASODILATATION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; AORTA, THORACIC; ARGINASE; BLOOD PRESSURE; CITRULLINE; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; HYPERINSULINISM; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; NITRIC OXIDE; ORNITHINE; RANDOM ALLOCATION; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; VALINE;

EID: 84877824517     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12144     Document Type: Article

References (42)

1. Berkowitz DE, White R, Li D, Minhas KM, Cernetich A, Kim S, et al. (2003). Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation 108: 2000-2006.
2. Bivalacqua TJ, Hellstrom WJ, Kadowitz PJ, Champion HC, (2001). Increased expression of arginase II in human diabetic corpus cavernosum: in diabetic-associated erectile dysfunction. Biochem Biophys Res Commun 283: 923-927.
3. Cederbaum SD, Yu H, Grody WW, Kern RM, Yoo P, Iyer RK, (2004). Arginases I and II: do their functions overlap? Mol Genet Metab 81 (Suppl. 1): S38-S44.
4. El-Bassossy HM, El-Maraghy NN, El-Fayoumi HM, Watson ML, (2009). Haem oxygenase-1 induction protects against tumour necrosis factor alpha impairment of endothelial-dependent relaxation in rat isolated pulmonary artery. Br J Pharmacol 158: 1527-1535.
5. El-Bassossy HM, El-Moselhy MA, Mahmoud MF, (2011a). Pentoxifylline alleviates vascular impairment in insulin resistance via TNF-α inhibition. Naunyn Schmiedebergs Arch Pharmacol 384: 277-285.
6. El-Bassossy HM, Fahmy A, Badawy D, (2011b). Cinnamaldehyde protects from the hypertension associated with diabetes. Food Chem Toxicol 49: 3007-3012.
7. El-Bassossy HM, Abo-Warda SM, Fahmy A, (2012a). Rosiglitazone, a PPARγ stimulant, abrogates diabetes-evoked hypertension via rectifying abnormalities in vascular reactivity. Clin Exp Pharmacol Physiol 39: 643-649.
8. El-Bassossy HM, Fahmy A, El-Fawal R, (2012b). Arginase inhibition alleviates hypertension associated with diabetes: effect on endothelial dependent relaxation and NO production. Vascul Pharmacol 57: 194-200.
9. El-Mas MM, El-Gowilly SM, Gohar EY, Ghazal AR, Abdel-Rahman AA, (2011). Estrogen dependence of the renal vasodilatory effect of nicotine in rats: role of α7 nicotinic cholinergic receptor/eNOS signaling. Life Sci 88: 187-193.
10. Ensunsa JL, Symons JD, Lanoue L, Schrader HR, Keen CL, (2004). Reducing arginase activity via dietary manganese deficiency enhances endothelium- dependent vasorelaxation of rat aorta. Exp Biol Med 229: 1143-1153.
11. Ford ES, Giles WH, Dietz WH, (2002). Prevalence of the metabolic syndrome among US adults: findings from the third national health and nutrition examination survey. JAMA 287: 356-359.
12. Fossati P, Prencipe L, Berti G, (1980). Use of 3,5-dichloro-2- hydroxybenzenesulfonic acid/4-aminophenazone chromogenic system in direct enzymic assay of uric acid in serum and urine. Clin Chem 26: 227-231.
13. Fuentes JM, Campo ML, Soler G, (1994). Kinetics and inhibition by some aminoacids of lactating rat mammary gland arginase. Arch Int Physiol Biochim Biophys 102: 255-258.
14. Goto T, Ohnomi S, Khedara A, Kato N, Ogawa H, Yanagita T, (1999). Feeding the nitric oxide synthase inhibitor L-N(omega)nitroarginine elevates serum very low density lipoprotein and hepatic triglyceride synthesis in rats. J Nutr Biochem 10: 274-278.
15. Gronros J, Jung C, Lundberg JO, Cerrato R, Ostenson CG, Pernow J, (2011). Arginase inhibition restores in vivo coronary microvascular function in type 2 diabetic rats. Am J Physiol Heart Circ Physiol 300: H1174-H1181.
16. Heinig M, Johnson RJ, (2006). Role of uric acid in hypertension, renal disease, and metabolic syndrome. Cleve Clin J Med 73: 1059-1064.
17. Hunter A, Downs CE, (1945). The inhibition of arginase by amino acids. J Biol Chem 157: 427-446.
18. Huynh NN, Harris EE, Chin-Dusting JF, Andrews KL, (2009). The vascular effects of different arginase inhibitors in rat isolated aorta and mesenteric arteries. Br J Pharmacol 156: 84-93.
19. Kang ES, Ford K, Grokulsky G, Wang YB, Chiang TM, Acchiardo SR, (2000). Normal circulating adult human red blood cells contain inactive NOS proteins. J Lab Clin Med 135: 444-451.
20. Kashyap SR, Lara A, Zhang R, Park YM, DeFronzo RA, (2008). Insulin reduces plasma arginase activity in type 2 diabetic patients. Diabetes Care 31: 134-139.
21. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
22. Kim J, Montagnani M, Koh KK, Quon MJ, (2006). Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 113: 1888-1904.
23. Kolovou GD, Anagnostopoulou KK, Cokkinos DV, (2005). Pathophysiology of dyslipidaemia in the metabolic syndrome. Postgrad Med J 81: 358-366.
24. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
25. Mahmoud MF, El-Nagar M, El-Bassossy HM, (2012). Anti-inflammatory effect of atorvastatin on vascular reactivity and insulin resistance in fructose fed rats. Arch Pharm Res 35: 155-162.
26. Mansour SM, Bahgat AK, El-Khatib AS, Khayyal MT, (2011). Ginkgo biloba extract (EGb 761) normalizes hypertension in 2K, 1C hypertensive rats: role of antioxidant mechanisms, ACE inhibiting activity and improvement of endothelial dysfunction. Phytomedicine 18: 641-647.
27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC, (1985). Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
28. Mendez JD, Sosa A, Palomar-Morales M, (2002). Effect of L-arginine on arginase activity in male accessory sex glands of alloxan-treated rats. Reprod Toxicol 16: 809-813.
29. Morris CR, Morris SM, Jr, Hagar W, van, Warmerdam J, Claster S, Kepka-Lenhart D, et al. (2003). Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med 168: 63-69.
30. Morris SM, Jr, Gao T, Cooper TK, Kepka-Lenhart D, Awad AS, (2011). Arginase-2 mediates diabetic renal injury. Diabetes 60: 3015-3022.
31. O'Rourke MF, Nichols WW, (2005). Aortic diameter, aortic stiffness, and wave reflection increase with age and isolated systolic hypertension. Hypertension 45: 652-658.
32. Robins SJ, Rubins HB, Faas FH, Schaefer EJ, Elam MB, Anderson JW, et al. (2003). Insulin resistance and cardiovascular events with low HDL cholesterol: the veterans affairs HDL intervention trial (VA-HIT). Diabetes Care 26: 1513-1517.
33. Romero MJ, Platt DH, Tawfik HE, Labazi M, El-Remessy AB, Bartoli M, et al. (2008). Diabetes-induced coronary vascular dysfunction involves increased arginase activity. Circ Res 102: 95-102.
34. Saad MF, Rewers M, Selby J, Howard G, Jinagouda S, Fahmi S, et al. (2004). Insulin resistance and hypertension: the insulin resistance atherosclerosis study. Hypertension 43: 1324-1331.
35. Santhanam L, Christianson DW, Nyhan D, Berkowitz DE, (2008). Arginase and vascular aging. J Appl Physiol 105: 1632-1642.
36. Schinzari F, Tesauro M, Rovella V, Galli A, Mores N, Porzio O, et al. (2010). Generalized impairment of vasodilator reactivity during hyperinsulinemia in patients with obesity-related metabolic syndrome. Am J Physiol Endocrinol Metab 299: E947-E952.
37. Shearer JD, Richards JR, Mills CD, Caldwell MD, (1997). Differential regulation of macrophage arginine metabolism: a proposed role in wound healing. Am J Physiol Endocrinol Metab 272: E181-E190.
38. Takagawa Y, Berger ME, Hori MT, Tuck ML, Golub MS, (2001). Long-term fructose feeding impairs vascular relaxation in rat mesenteric arteries. Am J Hypertens 14: 811-817.
39. Ugochukwu NH, Cobourne MK, (2003). Modification of renal oxidative stress and lipid peroxidation in streptozotocin-induced diabetic rats treated with extracts from Gongronema latifolium leaves. Clin Chim Acta 336: 73-81.
40. Verma S, Bhanot S, Yao L, McNeill JH, (1996). Defective endothelium-dependent relaxation in fructose-hypertensive rats. Am J Hypertens 9: 370-376.
41. Zand J, Lanza F, Garg HK, Bryan NS, (2011). All-natural nitrite and nitrate containing dietary supplement promotes nitric oxide production and reduces triglycerides in humans. Nutr Res 31: 262-269.
42. Zhang C, Hein TW, Wang W, Miller MW, Fossum TW, McDonald MM, et al. (2004). Upregulation of vascular arginase in hypertension decreases nitric oxide-mediated dilation of coronary arterioles. Hypertension 44: 935-943.